Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15427862 | 0.73 | PTK2 (0.42) | PTK2TP53CYP3A4THRBALOX15 | |
| SCHEMBL15428009 | 0.71 | SRD5A1 (0.38) | KDM4EMAPTMAPK1TP53ALOX15 | |
| SCHEMBL16905542 | 0.70 | PTK2 (0.44) | PTK2TP53CYP3A4THRBALOX15 | |
| SCHEMBL21440629 | 0.70 | PTK2 (0.44) | PTK2TP53CYP3A4THRBALOX15 | |
| SCHEMBL9867812 | 0.70 | PTK2 (0.44) | PTK2TP53CYP3A4THRBALOX15 | |
| SCHEMBL15427830 | 0.67 | PTK2 (0.40) | PTK2TP53CYP3A4THRBALOX15 | |
| SCHEMBL15428156 | 0.65 | PTK2 (0.44) | PTK2TP53CYP3A4THRBALOX15 | |
| SCHEMBL15427712 | 0.65 | PTK2 (0.38) | PTK2TP53CYP3A4THRBALOX15 | |
| SCHEMBL21440625 | 0.64 | RXRA (0.38) | PTK2TP53CYP3A4THRBALOX15 | |
| Hydrochloric Acid SCHEMBL17075278 | 0.64 | PTK2 (0.42) | PTK2TP53CYP3A4THRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014008982-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150263297-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | PTK2 3420/4885KDM4E 3816/4885GAA 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.